Role of fas ligand expression in promoting escape from immune rejection in a spontaneous tumor model

International Journal of Cancer

Volumn 91, Issue 4, 2001, Pages 529-537

  Cfai, Daniel ^a   Favre, Luc ^a   Wattendorf, Elise ^a   Marti, Andreas ^a   Jaggi, Rolf ^a   Gimmi, Claude D ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Fas L; HER 2 neu oncogene; Immune escape; Tumor vaccines

Indexed keywords

CANCER VACCINE; CELL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FAS ANTIGEN; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CELL SUSPENSION; CONTROLLED STUDY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; T LYMPHOCYTE; TUMOR ESCAPE;

3T3 CELLS; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CANCER VACCINES; CELL SEPARATION; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; GENES, MHC CLASS I; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES; MAMMARY NEOPLASMS, ANIMAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; POLYMERASE CHAIN REACTION; RATS; RECEPTOR, ERBB-2; T-LYMPHOCYTES; TIME FACTORS; UP-REGULATION;

EID: 0035866043     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1074>3.0.CO;2-O     Document Type: Article

References (49)

1. Human tumor antigens recognized by T lymphocytes
2. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
3. Tumor regression responses in melanoma patients treated with peptide encoded by gene MAGE-3
4. Vaccination of melanoma patients with peptide- or tumor lysatepulsed dendritic cells
5. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
6. Relapse after successful treatment with immunotherapy: Lessons for the future
7. Neoplastic cells that express low levels of MHC class I determinents escape host immunity
8. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas
9. Molecular mechanisms used by tumors to escape immune recognition: Immunogenetherapy and the cell biology of the major histocompatibility complex class I
10. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice
11. A novel role for TGF-beta and IL-10 in the induction of immune privilege
12. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance
13. TGF-beta contributes to the shift toward TH2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice
14. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor escape
15. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
16. Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells: A mechanism of immune evasion?
17. Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back
18. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
19. Fas-counterattack the best form of tumor defense
20. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer
21. ErbB-2 is a potent oncogene when overexpressed in NIH3T3 cells
22. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH3T3 cells
23. Diversification of the Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
24. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
25. p185 neu expression in human lung adenocarcinomas predicts shortened survival
26. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
27. Evaluation of immunoreactivity for ErbB-2 as worker of poor short term prognosis in gastric cancer
28. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene
29. Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer
30. Neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2 initiated tumors
31. In situ immunodetection of activated caspase-3 in apoptotic neurons in the developing nervous system
32. Virus persistence in actually infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells
33. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy
34. Expression of Fas ligand (CD95/APO-1) by human breast cancers: Significance for tumor privilege
35. Down-regulation of major histocompatibility complex Class I expression in mammary carcinoma of HER-2/neu transgenic mice
36. A role for CD95 ligand in preventing graft rejection
37. Fas ligand-induced apoptosis as a mechanism of immune privilege
38. Stability of HER-2/neu expression over time and at multiple metastatic sites
39. Tumor counterattack-concept and reality
40. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape
41. Fas ligand expression in islets Langerhans does not confer immune privilege and instead targets them for rapid destruction
42. Gene transfer of Fas ligand induces tumor regression in vitro
43. Antitumor effect of locally produced CD95 ligand
44. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts
45. Attempts to reveal the mechanism of CD95-ligand mediated inflammation
46. Expression of Fas (Apo/ CD95) ligand in tumor-infiltrating and peripheral lymphocytes in patients with renal cell carcinoma
47. Induction of apoptosis in mature T cells by tumor necrosis factor
48. The Fas/Fas-ligand system: A mechanism for immune evasion in human breast carcinomas
49. CD95 ligand expression as a mechanism of immune escape in breast cancer